TaiGen Biopharmaceuticals Holdings Statistics

Total Valuation

TaiGen Biopharmaceuticals Holdings has a market cap or net worth of TWD 7.82 billion. The enterprise value is 6.83 billion.

Market Cap	7.82B
Enterprise Value	6.83B

Important Dates

The next estimated earnings date is Friday, March 21, 2025.

Earnings Date	Mar 21, 2025
Ex-Dividend Date	n/a

Share Statistics

TaiGen Biopharmaceuticals Holdings has 717.84 million shares outstanding. The number of shares has increased by 0.12% in one year.

Current Share Class	n/a
Shares Outstanding	717.84M
Shares Change (YoY)	+0.12%
Shares Change (QoQ)	-0.01%
Owned by Insiders (%)	2.60%
Owned by Institutions (%)	5.08%
Float	420.99M

Valuation Ratios

The trailing PE ratio is 45.67.

PE Ratio	45.67
Forward PE	n/a
PS Ratio	52.57
PB Ratio	7.03
P/TBV Ratio	7.10
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	39.75
EV / Sales	45.89
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-59.06

Financial Position

The company has a current ratio of 19.30, with a Debt / Equity ratio of 0.06.

Current Ratio	19.30
Quick Ratio	18.40
Debt / Equity	0.06
Debt / EBITDA	n/a
Debt / FCF	-0.54
Interest Coverage	-101.72

Financial Efficiency

Return on equity (ROE) is 16.97% and return on invested capital (ROIC) is -8.86%.

Return on Equity (ROE)	16.97%
Return on Assets (ROA)	-8.52%
Return on Capital (ROIC)	-8.86%
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	n/a
Asset Turnover	0.13
Inventory Turnover	0.34

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -29.45% in the last 52 weeks. The beta is 0.76, so TaiGen Biopharmaceuticals Holdings's price volatility has been lower than the market average.

Beta (5Y)	0.76
52-Week Price Change	-29.45%
50-Day Moving Average	12.87
200-Day Moving Average	14.33
Relative Strength Index (RSI)	20.85
Average Volume (20 Days)	1,389,551

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, TaiGen Biopharmaceuticals Holdings had revenue of TWD 148.75 million and earned 171.74 million in profits. Earnings per share was 0.24.

Revenue	148.75M
Gross Profit	134.95M
Operating Income	-153.49M
Pretax Income	175.81M
Net Income	171.74M
EBITDA	-144.67M
EBIT	-153.49M
Earnings Per Share (EPS)	0.24

Full Income Statement

Balance Sheet

The company has 1.06 billion in cash and 62.74 million in debt, giving a net cash position of 997.41 million or 1.39 per share.

Cash & Cash Equivalents	1.06B
Total Debt	62.74M
Net Cash	997.41M
Net Cash Per Share	1.39
Equity (Book Value)	1.11B
Book Value Per Share	1.55
Working Capital	1.07B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -114.88 million and capital expenditures -716,000, giving a free cash flow of -115.60 million.

Operating Cash Flow	-114.88M
Capital Expenditures	-716,000
Free Cash Flow	-115.60M
FCF Per Share	-0.16

Full Cash Flow Statement

Margins

Gross margin is 90.72%, with operating and profit margins of -103.19% and 115.46%.

Gross Margin	90.72%
Operating Margin	-103.19%
Pretax Margin	118.19%
Profit Margin	115.46%
EBITDA Margin	-97.26%
EBIT Margin	-103.19%
FCF Margin	n/a

Dividends & Yields

TaiGen Biopharmaceuticals Holdings does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-0.12%
Shareholder Yield	-0.12%
Earnings Yield	2.19%
FCF Yield	-1.48%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

TaiGen Biopharmaceuticals Holdings has an Altman Z-Score of 60.54.

Altman Z-Score	60.54
Piotroski F-Score	n/a